vTv Therapeutics is a clinical-stage biopharmaceutical company dedicated to enhancing the lives of patients with diabetes through the development of oral, small molecule drug candidates. The company's lead candidate, cadisegliatin, is being investigated as a potential adjunctive therapy to insulin for individuals with type 1 diabetes. In addition to this primary focus, vTv is also exploring other indications, including type 2 diabetes and various chronic conditions, showcasing a commitment to addressing a broad spectrum of metabolic disorders.

The company's pipeline reflects its innovative approach to drug development, emphasizing the potential of small molecule therapies to provide effective treatment options. By collaborating with development partners, vTv aims to expand its therapeutic offerings and improve patient outcomes in diabetes management. The ongoing research and development efforts underscore vTv's dedication to advancing science and delivering meaningful solutions for patients facing chronic health challenges.

United States

vTv Therapeutics is a clinical stage biopharmaceutical company focused on developing oral, small molecule drug candidates. vTv has a pipeline of clinical drug candidates led by cadisegliatin, a potential adjunctive therapy to insulin for the treatment of type 1 diabetes. vTv and its development partners are pursuing additional indications, including type 2 diabetes and other chronic conditions.

Endocrine System Diseases

Genetic Diseases

Kidney Diseases

Lung Diseases

Metabolic Diseases

Skin Diseases

vTv Therapeutics

Diabetes

Type 1 diabetes

Glucokinase (GK) is a key regulator of glucose homeostasis and acts as the physiological glucose sensor, changing its conformation, activity, and/or intracellular location in parallel with changes in glucose concentrations. GK has two main distinctive characteristics that make it a good choice for blood glucose control. First, its expression is mostly limited to tissues that require glucose-sensing (mainly liver and pancreatic β-cells). Second, GK is able to sense changes in serum glucose levels and modulate changes in liver glucose metabolism that in turn regulate the balance between hepatic glucose production (HGP) and glucose consumption, and to modulate changes in insulin secretion by the beta-cells. The concept of GK activation for the treatment of diabetes is attractive because it has proven to be effective and safe in normalizing glycemia in animal models of type 1 and type 2 diabetes by a mechanism entirely distinct from the action of antidiabetic therapies currently on the market.

Cadisegliatin (TTP399) 

Psoriasis

Skin disease/disorder

Inhibitors of phosphodiesterase type 4 (PDE4) act by increasing intracellular concentrations of cyclic AMP, which has a broad range of anti-inflammatory effects. However, the therapeutic potential of PDE4 inhibitors has been limited by dose limiting adverse events such as nausea and emesis.

HPP737 

Type 2 diabetes

Cystic fibrosis

GLP-1 is a member of the incretin family of neuroendocrine peptide hormones secreted from L-cells of the intestine in response to food ingestion. GLP-1 has multiple metabolic effects that are attractive for an anti-diabetic agent, which have been validated by existing injectable peptide GLP-1R agonists.

TTP273 (Oral GLP-1R)

Alzheimer's disease

Dementia

Frontotemporal dementia with C9orf72 mutation

Neurological disorder

RAGE is an immunoglobulin-like cell surface receptor that is overexpressed in brain tissues of patients with AD. The multiligand nature of RAGE is highlighted by its ability to bind diverse ligands such as advanced glycation end-products (AGEs), linked to diabetic complications and β-amyloid fibrils, a hallmark of AD. The association between type 2 diabetes and AD is well documented. A linear correlation between circulating hemoglobin A1c (HbA1c) levels and cognitive decline has been demonstrated in the English Longitudinal Study of Ageing.

vTv Therapeutics

Company Details